Prenatal 60K Chromosomal Microarray (AF/CVS) with Karyotyping

Executive Summary & Core Metrics

Our DHA-licensed laboratory (License 1143) offers the Prenatal 60K Chromosomal Microarray combined with full karyotyping for comprehensive fetal genomic assessment. This test provides 99.9% diagnostic sensitivity for detecting chromosomal abnormalities, including submicroscopic copy number variants. Sample collection is a hospital-only procedure (amniocentesis or chorionic villus sampling) performed under ultrasound guidance. Turnaround time is 7–9 working days. Post-test telephonic clinical guidance is provided by a board-certified geneticist.

✓ Diagnostic Accuracy: 99.9% sensitivity, ISO 9001:2015

✓ Hospital-Only Collection: Invasive procedure by OB/GYN

✓ Post-Test Guidance: Telephonic interpretation by DHA-licensed geneticist

Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731

Test Overview & Methodology

This combined test utilizes Agilent 60K oligonucleotide microarray technology to detect submicroscopic deletions and duplications (~60 kb resolution) alongside traditional G-banded karyotyping for aneuploidies and structural rearrangements. The integration of both methods yields up to 12% additional pathogenic findings compared to karyotyping alone, providing a complete fetal genomic picture.

Feature	60K Microarray + Karyotype	Conventional Karyotype Only
Resolution	~60 kb deletions/duplications	5–10 Mb (light microscopy)
Methodology	Agilent 60K microarray + G-band karyotyping (cell culture)	G-band karyotyping only
Diagnostic Yield	Up to 12% additional pathogenic findings	Standard yield for aneuploidy/translocations
TAT	7–9 working days	14–21 working days

Physician Insight & Safety Protocols

“The combination of high-resolution microarray and conventional karyotyping offers a comprehensive evaluation of fetal chromosomal health. I recommend this test for patients with abnormal ultrasound findings or a family history of genetic disorders. Please note that results require careful interpretation in conjunction with clinical and ultrasound data. Always discuss findings with your obstetrician or genetic counselor before making any clinical decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License: 9294403

Advisory – Safety Protocols for Invasive Sampling

Amniocentesis and chorionic villus sampling are invasive procedures that carry a small risk of miscarriage (approximately 1 in 500). These procedures are performed under continuous ultrasound guidance by experienced OB/GYNs. Patients are advised to rest for 24 hours post-procedure and to avoid strenuous activity. Any unusual symptoms such as fever, severe abdominal pain, or vaginal bleeding should be reported immediately.

Exclusion Criteria & Emergency Red Flags

Active maternal infection (sepsis, uterine infection) – immediate medical attention.
Severe vaginal bleeding or signs of threatened abortion.
Known cervical insufficiency without cerclage – CVS is contraindicated.
Uncontrolled hypertension or coagulopathy – increases procedural risk.
If you experience sharp abdominal pain, fever, or leaking amniotic fluid after collection, seek emergency obstetric care.

Patient FAQ & Clinical Guidance

1. What is the advantage of combining 60K microarray with karyotyping?

The combined test detects both microscopic chromosomal anomalies (aneuploidies, translocations) via karyotyping and submicroscopic copy number variations through the 60K microarray. This dual approach increases the diagnostic yield, identifying up to 12% more clinically significant findings than karyotyping alone.

2. How is the sample collected and what are the risks?

Sample collection is performed by a qualified OB/GYN through amniocentesis or chorionic villus sampling under ultrasound guidance. These are hospital-only procedures. Risks include a small chance of miscarriage (1 in 500) and temporary discomfort. The laboratory provides cold-chain transport for the collected sample to ensure integrity.

3. When can I expect results and how are they reported?

Results are delivered within 7–9 working days. The report includes a detailed interpretation from a consultant medical geneticist and is accompanied by telephonic post-test guidance to explain pathogenic findings and recommend next steps.

UAE Regulatory & Data Privacy Adherence

This laboratory operates in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted and accessed only by authorized personnel. Clinical procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure patient safety and informed consent. The facility is licensed by the Dubai Health Authority (License 1143) and adheres to ISO 9001:2015 quality management standards (Cert: INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	Prenatal 60K Chromosomal Microarray (AF/CVS) with Karyotyping
Price (AED)	3,000 AED
Turnaround Time	7–9 working days
Sample Type / Matrix	Amniotic Fluid (AF) or Chorionic Villus Sampling (CVS) – Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Methodology Used	Agilent 60K oligonucleotide microarray + G-band karyotyping
ICD-10-CM Code	O35.1
LOINC Code	81248-4
DHA Facility License & Laboratory Address	DHA License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE